Hemab Therapeutics Holdings Inc. – Material Contracts Watch

from S-1/A 11 pages Master Service Agreement

from S-1/A 3 pages Hemab Therapeutics Holdings, Inc. Non-Employee Director Compensation Policy

from S-1/A 19 pages Indemnification Agreement

from S-1/A 15 pages December 24, 2024 Catherine Madigan Re: Employment Offer Dear Kate: I Am Pleased to Offer You Employment With Hemab Therapeutics (“Hemab” or the “Company”). the Initial Terms and Conditions of Your Employment, Should You Accept This Offer, Are Set Forth Below (The “Agreement”)

from S-1/A 22 pages Service Agreement Hemab Aps Between Hemab Aps and Mads Behrndt Dated 22 July 2021 Service Agreement Entered Into Between Hemab Aps Ole Maaløes Vej 3 Dk-2200 Copenhagen N Cvr-No. 40837590 (The “Company”) and Mads Behrndt [**] (The “CFO”) 1. Date of Employment 1.1 the CFO Will Take Up the Position as Chief Financial Officer of the Company as From 1 September 2021 and Be Registered as Such With the Danish Business Authority. 1.2 This Service Agreement Shall Replace and Supersede Any Prior Agreement Between the CFO and the Company. 2. the Duties of the CFO

from S-1/A 17 pages Executive Employment Agreement

from S-1/A 7 pages Hemab Therapeutics Holdings, Inc. 2026 Employee Stock Purchase Plan

from S-1/A 5 pages Hemab Therapeutics Holdings, Inc. Stock Option Agreement

from S-1/A 18 pages Hemab Therapeutics Holdings, Inc. 2026 Equity Incentive Plan

from S-1 32 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions

from S-1 26 pages Certain Portions of This Exhibit Have Been Omitted Because They Are Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. License Agreement for Biab Fvii/Tlt-1 by and Between Novo Nordisk a/S and Ebumab Hemophilia Aps Effective Date 22 November 2019 License Agreement

from DRS 32 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions

from DRS 26 pages Certain Portions of This Exhibit Have Been Omitted Because They Are Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. License Agreement for Biab Fvii/Tlt-1 by and Between Novo Nordisk a/S and Ebumab Hemophilia Aps Effective Date 22 November 2019 License Agreement